Dr Eloísa Riva speaks to ecancer at the ASH 2019 meeting in Orlando about the main highlights from the meeting.

She begins by highlighting the emergence of new tools for the detection of monoclonal proteins, including the use of mass spectrometry.  

Dr Riva also discusses the use of quadruple therapy, which has shown to increase the overall response rate and depth of response compared to triple therapy.

She also explains the latest developments in triple-refractory disease, including the STOMP trial and the TOURMALINE-AL1 for patients with relapsed/refractory primary systemic AL amyloidosis.

Dr Riva concludes by stating the importance of this meeting for Latin American research groups, as it provides them with the opportunity for collaboration, education and training.